Overview
Lobbying Costs
10,000€ - 24,999€
Financial year: Jan 2023 - Dec 2023
Lobbyists (Full time equivalent)
0.25 Fte (1)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
argenx
EU Transparency Register
438972049913-07 First registered on 21 Apr 2023
Goals / Remit
We are a commercial-stage, global, fully-integrated biopharma company developing
a deep pipeline of differentiated therapies for the treatment of severe autoimmune
diseases. By combining our suite of antibody engineering technologies with the disease
biology expertise of our research collaborators, we aim to translate immunology
breakthroughs into a pipeline of novel antibody-based medicines through our discovery
engine, the IIP. We have a particular focus on rare, autoimmune diseases that fit into our
growing commercial franchises focused on neurology, hematology and rheumatology,
dermatology and nephrology.Main EU files targeted
At this stage, argenx activities in the field of public policy in general and at EU level in particular is fairly limited and include legislative and policy monitoring, and some direct and indirect engagement via trade association EUCOPE. We expect this engagement to increase in the context of the Reform of EU pharmaceutical legislation.
In addition, argenx supports All United for MG - a pan european patient group coalition (https://www.allunitedformg.eu/) which is expected to present a series of policy recommendations to EU officials with different implications for EU policies and legislation.
Key legislative topics relate to EU pharmaceutical and health policy and in particular Reform of the EU pharmaceutical legislation published on April 26.
https://health.ec.europa.eu/publications/proposal-regulation-laying-down-union-procedures-authorisation-and-supervision-medicinal-products_enAddress
Head Office
Industriepark Zwijnaarde 7, 9052 Gent
Ghent 9052
BELGIUMEU Office
Industriepark Zwijnaarde 7, 9052 Gent
Ghent 9052
BELGIUM -
People
Total lobbyists declared
1
Employment time Lobbyists 25% 1 Lobbyists (Full time equivalent)
0.25
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
argenx Patient Advocacy and Public Policy team for the entire European region is composed of two FTEs. Those FTEs are responsible for a broad range of activities across countries in Europe Middle East and Africa.
In addition, activities at EU level are limited and therefore constitute a very limited share of the work of the patient advocacy and public policy team (see above)Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Companies & groups
-
Networking
Affiliation
EUCOPE https://www.eucope.org/
EURORDIS (ERTC) https://www.eurordis.org/Member organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2023 - Dec 2023
Lobbying costs for closed financial year
10,000€ - 24,999€
Major contributions in closed year
None declared
Intermediaries for closed year
Name Amount portland pr europe limited (portland) 100,000€ - 199,999€ Intermediaries for current year
Name fti consulting belgium Closed year Costs
10,000€ - 24,999€
Other financial info
Portland PR Europe Limited has supported argenx in 2022 and 2023. On a go forward basis, argenx may not use intermediary any further. Transparency register will be updated accordingly.
-
EU Structures
Groups (European Commission)
None declared
Groups (European Parliament)
N/A
Communication activities
argenx supported myastenia gravis patient advocacy groups in the all united for MG campaign, which includes some disease awareness activities and events at European Parliament. While supported by argenx, those activities are driven by Patient Advocacy Groups across Europe.
Other activities
None declared
Meetings
Meetings
None declared